Recent Findings from National Health Insurance Service Ilsan Hospital Provides New Insights into Non-Small Cell Lung Cancer (Clinical and Financial Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy In Patients With Advanced …): Oncology – Non-Small Cell Lung Cancer

2024 MAY 01 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- A new study on Oncology - Non-Small Cell Lung Cancer is now available. According to news reporting originating from Goyang, South Korea, by NewsRx correspondents, research stated, “Although various studies have demonstrated that the clinical efficacy of immune checkpoint inhibitors (ICIs) improves the prognosis of patients with non -small cell lung cancer (NSCLC), studies on the financial aspects based on large population -based data are needed. This study aimed to analyze the differences in medical expenses and the effect of ICIs on the prognosis of patients with advanced or metastatic NSCLC.”

Financial support for this research came from NHIS Ilsan Hospital grant.

Our news editors obtained a quote from the research from National Health Insurance Service Ilsan Hospital, “Patients newly diagnosed with stage IIIB or IV NSCLC who received palliative chemotherapy between 2013 and 2020 were selected from the nationwide database of the population covered by the Korean National Health Insurance Service. Interrupted time -series analysis was performed to evaluate the effects of subsequent ICI use after platinum -based cytotoxic chemotherapy (CC) on overall mortality. Progression -free survival and medical expenditure were also assessed. In the final study population, 2,485 and 4,812 patients were included in the ICI and non -ICI groups, respectively. ICI treatment significantly lowered the risk of death [adjusted hazard ratio, 0.79; 95% confidence interval (CI): 0.75-0.84]. And the ICI -treated patients were less likely to experience disease progression (adjusted odds ratios, 0.92; 95% CI: 0.85-0.99). Furthermore, after the introduction of ICIs, both total and cancer -related medical expenses per capita showed an increasing trend [(3: $4.56K, standard error (SE): $0.27K, P<0.0001 and (3: $4.54K, SE: $0.27K, P<0.0001, respectively]. Subsequent ICI use after platinum -based CC improved the overall survival rate of patients with advanced NSCLC.”

According to the news editors, the research concluded: “With the increasing burden of individual medical expenses, further research is required to identify patients for whom ICI treatment may be effective.”

This research has been peer-reviewed.

For more information on this research see: Clinical and Financial Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy In Patients With Advanced or Metastatic Non-small Cell Lung Cancer: a Nationwide Population-based Study. Translational Lung Cancer Research, 2024;13(1). Translational Lung Cancer Research can be contacted at: Ame Publishing Company, Flat-Rm C 16F, Kings Wing Plaza 1, No 3 Kwan St, Shatin, Hong Kong 00000, Peoples R China.

The news editors report that additional information may be obtained by contacting Sang Chul Lee, National Health Insurance Service Ilsan Hospital, Dept Res & Anal, Goyang, South Korea. Additional authors for this research include Sungyoun Chun and Chi Young Kim.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.21037/tlcr-23-686. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)